Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$5.10 USD
-0.22 (-4.14%)
Updated May 29, 2024 04:00 PM ET
After-Market: $5.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.10 USD
-0.22 (-4.14%)
Updated May 29, 2024 04:00 PM ET
After-Market: $5.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
GW Pharmaceuticals (GWPH) Q2 Earnings: What to Expect?
by Zacks Equity Research
GW Pharmaceuticals plc (GWPH) is expected to report second-quarter fiscal 2017 results on May 4.
What's in the Cards for ACADIA (ACAD) this Earnings Season?
by Zacks Equity Research
ACADIA Pharmaceuticals Inc. (ACAD) is expected to report first-quarter 2017 results on May 4.
Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store?
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report first-quarter results on May 4 before market open.
Allergan (AGN) and Editas Tie Up to Treat Eye Diseases
by Zacks Equity Research
Allergan plc's (AGN), and Editas Medicine, Inc. (EDIT), entered into a strategic research and development agreement.
Editas Medicine (EDIT) Shares March Higher, Can It Continue?
by Zacks Equity Research
Editas Medicine, Inc. (EDIT) has been on the move lately as the stock has risen by 6.6% in the past four weeks, and it is currently trading well above its 20-Day SMA